
Sun Pharmaceutical Industries share price
NSE: SUNPHARMA · Healthcare
₹1,867.50 -0.66%
Closing price data, updated 17 Nov 2026. 52-week range: -8.8% from high, +17.9% above low.
Price₹1,867.50
Market cap₹4,48,076 Cr
P/E40.9
P/B5.02
ROE14.7%
ROCE17.9%
Debt / equity0.06
Dividend yield0.00%
EPS₹45.70
Book value₹372.10
Operating margin23.4%
Dipscan score53 / 100
Share: WhatsAppX / TwitterTelegram
Sun Pharmaceutical Industries shareholding pattern
As of Sep 2026: Promoters 52.68%, FIIs 14.36%, DIIs 22.27%, Government 0.00%, Public 6.71%, Others 3.99%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 52.68% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| FIIs | 14.36% | 14.53% | 15.93% | 16.12% | 16.55% | 17.26% |
| DIIs | 22.27% | 22.18% | 21.11% | 20.82% | 20.23% | 19.50% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 6.71% | 5.48% | 5.30% | 5.40% | 5.53% | 5.35% |
| Others | 3.99% | 3.33% | 3.18% | 3.18% | 3.20% | 3.42% |
| No. of Shareholders | 714,266 | 710,246 | 690,957 | 710,900 | 743,877 | 723,770 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -0.66% | +0.40% | +6.93% | -3.34% | +0.23% | +8.82% |
Growth
| Sales growth, 3 years | +10.4% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +10.7% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | – |
| Latest quarter profit vs last year | – |
Strengths and weaknesses
Strengths
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 34.1%
Weaknesses
- Promoter holding has decreased over last quarter: -1.80%
- The company has delivered a poor sales growth of 11.8% over past five years.
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
| Mankind Pharma Ltd. | ₹2,626.60 | ₹1,08,490 Cr | 48.4 | 12.5% | +18.3% |
Frequently asked questions
What is the share price of Sun Pharmaceutical Industries ?
Sun Pharmaceutical Industries (SUNPHARMA) last closed at ₹1,867.50 (-0.66% on the day).
What is the market cap of Sun Pharmaceutical Industries ?
About ₹4,48,076 Cr.
What is the P/E ratio of Sun Pharmaceutical Industries ?
The price-to-earnings ratio is 40.9, and return on equity is 14.7%.
Figures are calculated from company results and exchange prices and are for information only.